Does the media favor ADPT or RVTY?

In the previous week, Revvity had 23 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 32 mentions for Revvity and 9 mentions for Adaptive Biotechnologies. Adaptive Biotechnologies' average media sentiment score of 1.41 beat Revvity's score of 0.98 indicating that Adaptive Biotechnologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adaptive Biotechnologies 7 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Revvity 17 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ADPT or ICLR?

In the previous week, Adaptive Biotechnologies had 4 more articles in the media than Icon. MarketBeat recorded 9 mentions for Adaptive Biotechnologies and 5 mentions for Icon. Adaptive Biotechnologies' average media sentiment score of 1.41 beat Icon's score of 0.91 indicating that Adaptive Biotechnologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adaptive Biotechnologies 7 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Icon 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ADPT or TECH?

In the previous week, Bio-Techne had 18 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 27 mentions for Bio-Techne and 9 mentions for Adaptive Biotechnologies. Adaptive Biotechnologies' average media sentiment score of 1.41 beat Bio-Techne's score of 1.40 indicating that Adaptive Biotechnologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adaptive Biotechnologies 7 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bio-Techne 21 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ADPT or RGEN?

In the previous week, Repligen had 11 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 20 mentions for Repligen and 9 mentions for Adaptive Biotechnologies. Adaptive Biotechnologies' average media sentiment score of 1.41 beat Repligen's score of 1.33 indicating that Adaptive Biotechnologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adaptive Biotechnologies 7 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Repligen 17 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Adaptive Biotechnologies (ADPT) Competitors

$25.19 -1.25 (-4.73%)

As of 08/28/2026 04:00 PM Eastern

Compare

ADPT vs. CRL, RVTY, ICLR, TECH, and RGEN

Should you buy Adaptive Biotechnologies stock or one of its competitors? Adaptive Biotechnologies's main competitors and comparable companies include Charles River Laboratories International (CRL), Revvity (RVTY), Icon (ICLR), Bio-Techne (TECH), and Repligen (RGEN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Adaptive Biotechnologies compare to Charles River Laboratories International?

Charles River Laboratories International (NYSE:CRL) and Adaptive Biotechnologies (NASDAQ:ADPT) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.

In the previous week, Charles River Laboratories International had 12 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 21 mentions for Charles River Laboratories International and 9 mentions for Adaptive Biotechnologies. Adaptive Biotechnologies' average media sentiment score of 1.41 beat Charles River Laboratories International's score of 0.36 indicating that Adaptive Biotechnologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Charles River Laboratories International	4 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Adaptive Biotechnologies	7 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Adaptive Biotechnologies has lower revenue, but higher earnings than Charles River Laboratories International. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Charles River Laboratories International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Charles River Laboratories International	$4.00B	3.48	-$144.34M	-$4.85	N/A
Adaptive Biotechnologies	$308.08M	13.05	-$59.50M	-$0.41	N/A

Charles River Laboratories International currently has a consensus target price of $255.65, indicating a potential downside of 12.39%. Adaptive Biotechnologies has a consensus target price of $24.42, indicating a potential downside of 3.07%. Given Adaptive Biotechnologies' higher probable upside, analysts plainly believe Adaptive Biotechnologies is more favorable than Charles River Laboratories International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Charles River Laboratories International	1 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.69
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Charles River Laboratories International has a net margin of -5.96% compared to Adaptive Biotechnologies' net margin of -20.73%. Charles River Laboratories International's return on equity of 15.75% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Charles River Laboratories International	-5.96%	15.75%	6.51%
Adaptive Biotechnologies	-20.73%	-36.81%	-13.77%

98.9% of Charles River Laboratories International shares are held by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are held by institutional investors. 1.3% of Charles River Laboratories International shares are held by insiders. Comparatively, 5.7% of Adaptive Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Charles River Laboratories International has a beta of 1.38, suggesting that its share price is 38% more volatile than the broader market. Comparatively, Adaptive Biotechnologies has a beta of 2.08, suggesting that its share price is 108% more volatile than the broader market.

Summary

Charles River Laboratories International and Adaptive Biotechnologies tied by winning 8 of the 16 factors compared between the two stocks.

How does Adaptive Biotechnologies compare to Revvity?

Adaptive Biotechnologies (NASDAQ:ADPT) and Revvity (NYSE:RVTY) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment and earnings.

Adaptive Biotechnologies currently has a consensus target price of $24.42, indicating a potential downside of 3.07%. Revvity has a consensus target price of $108.36, indicating a potential downside of 15.92%. Given Adaptive Biotechnologies' stronger consensus rating and higher probable upside, equities analysts plainly believe Adaptive Biotechnologies is more favorable than Revvity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Revvity	0 Sell rating(s)	12 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

Adaptive Biotechnologies has a beta of 2.08, suggesting that its share price is 108% more volatile than the broader market. Comparatively, Revvity has a beta of 1.07, suggesting that its share price is 7% more volatile than the broader market.

Revvity has higher revenue and earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adaptive Biotechnologies	$308.08M	13.05	-$59.50M	-$0.41	N/A
Revvity	$2.86B	5.04	$241.20M	$2.10	61.37

Revvity has a net margin of 8.16% compared to Adaptive Biotechnologies' net margin of -20.73%. Revvity's return on equity of 8.34% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adaptive Biotechnologies	-20.73%	-36.81%	-13.77%
Revvity	8.16%	8.34%	5.01%

In the previous week, Revvity had 23 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 32 mentions for Revvity and 9 mentions for Adaptive Biotechnologies. Adaptive Biotechnologies' average media sentiment score of 1.41 beat Revvity's score of 0.98 indicating that Adaptive Biotechnologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adaptive Biotechnologies	7 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Revvity	17 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.2% of Adaptive Biotechnologies shares are held by institutional investors. Comparatively, 86.7% of Revvity shares are held by institutional investors. 5.7% of Adaptive Biotechnologies shares are held by insiders. Comparatively, 0.9% of Revvity shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Adaptive Biotechnologies and Revvity tied by winning 8 of the 16 factors compared between the two stocks.

How does Adaptive Biotechnologies compare to Icon?

Adaptive Biotechnologies (NASDAQ:ADPT) and Icon (NASDAQ:ICLR) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

In the previous week, Adaptive Biotechnologies had 4 more articles in the media than Icon. MarketBeat recorded 9 mentions for Adaptive Biotechnologies and 5 mentions for Icon. Adaptive Biotechnologies' average media sentiment score of 1.41 beat Icon's score of 0.91 indicating that Adaptive Biotechnologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adaptive Biotechnologies	7 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Icon	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Adaptive Biotechnologies has a beta of 2.08, suggesting that its share price is 108% more volatile than the broader market. Comparatively, Icon has a beta of 1.21, suggesting that its share price is 21% more volatile than the broader market.

99.2% of Adaptive Biotechnologies shares are held by institutional investors. Comparatively, 95.6% of Icon shares are held by institutional investors. 5.7% of Adaptive Biotechnologies shares are held by insiders. Comparatively, 44.0% of Icon shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Adaptive Biotechnologies currently has a consensus price target of $24.42, suggesting a potential downside of 3.07%. Icon has a consensus price target of $170.40, suggesting a potential upside of 0.22%. Given Icon's higher probable upside, analysts plainly believe Icon is more favorable than Adaptive Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Icon	2 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.41

Icon has higher revenue and earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Icon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adaptive Biotechnologies	$308.08M	13.05	-$59.50M	-$0.41	N/A
Icon	$8.29B	1.57	$229.34M	$4.26	39.91

Icon has a net margin of 3.99% compared to Adaptive Biotechnologies' net margin of -20.73%. Icon's return on equity of 8.02% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adaptive Biotechnologies	-20.73%	-36.81%	-13.77%
Icon	3.99%	8.02%	4.56%

Summary

Icon beats Adaptive Biotechnologies on 11 of the 17 factors compared between the two stocks.

How does Adaptive Biotechnologies compare to Bio-Techne?

Adaptive Biotechnologies (NASDAQ:ADPT) and Bio-Techne (NASDAQ:TECH) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, media sentiment, institutional ownership, profitability and dividends.

Adaptive Biotechnologies has a beta of 2.08, meaning that its stock price is 108% more volatile than the broader market. Comparatively, Bio-Techne has a beta of 1.28, meaning that its stock price is 28% more volatile than the broader market.

99.2% of Adaptive Biotechnologies shares are held by institutional investors. Comparatively, 99.0% of Bio-Techne shares are held by institutional investors. 5.7% of Adaptive Biotechnologies shares are held by company insiders. Comparatively, 1.3% of Bio-Techne shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Bio-Techne has a net margin of 14.97% compared to Adaptive Biotechnologies' net margin of -20.73%. Bio-Techne's return on equity of 13.23% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adaptive Biotechnologies	-20.73%	-36.81%	-13.77%
Bio-Techne	14.97%	13.23%	10.61%

Bio-Techne has higher revenue and earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adaptive Biotechnologies	$308.08M	13.05	-$59.50M	-$0.41	N/A
Bio-Techne	$1.22B	9.34	$181.86M	$1.15	62.91

In the previous week, Bio-Techne had 18 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 27 mentions for Bio-Techne and 9 mentions for Adaptive Biotechnologies. Adaptive Biotechnologies' average media sentiment score of 1.41 beat Bio-Techne's score of 1.40 indicating that Adaptive Biotechnologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adaptive Biotechnologies	7 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bio-Techne	21 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Adaptive Biotechnologies presently has a consensus price target of $24.42, suggesting a potential downside of 3.07%. Bio-Techne has a consensus price target of $68.92, suggesting a potential downside of 4.74%. Given Adaptive Biotechnologies' stronger consensus rating and higher possible upside, equities analysts clearly believe Adaptive Biotechnologies is more favorable than Bio-Techne.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Bio-Techne	0 Sell rating(s)	15 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.12

Summary

Adaptive Biotechnologies and Bio-Techne tied by winning 8 of the 16 factors compared between the two stocks.

How does Adaptive Biotechnologies compare to Repligen?

Adaptive Biotechnologies (NASDAQ:ADPT) and Repligen (NASDAQ:RGEN) are both mid-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.

99.2% of Adaptive Biotechnologies shares are owned by institutional investors. Comparatively, 97.6% of Repligen shares are owned by institutional investors. 5.7% of Adaptive Biotechnologies shares are owned by insiders. Comparatively, 0.6% of Repligen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Repligen has a net margin of 5.29% compared to Adaptive Biotechnologies' net margin of -20.73%. Repligen's return on equity of 5.30% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adaptive Biotechnologies	-20.73%	-36.81%	-13.77%
Repligen	5.29%	5.30%	3.79%

Adaptive Biotechnologies presently has a consensus target price of $24.42, suggesting a potential downside of 3.07%. Repligen has a consensus target price of $166.43, suggesting a potential downside of 5.58%. Given Adaptive Biotechnologies' higher possible upside, equities analysts plainly believe Adaptive Biotechnologies is more favorable than Repligen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Repligen	0 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	3.00

In the previous week, Repligen had 11 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 20 mentions for Repligen and 9 mentions for Adaptive Biotechnologies. Adaptive Biotechnologies' average media sentiment score of 1.41 beat Repligen's score of 1.33 indicating that Adaptive Biotechnologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adaptive Biotechnologies	7 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Repligen	17 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Adaptive Biotechnologies has a beta of 2.08, suggesting that its share price is 108% more volatile than the broader market. Comparatively, Repligen has a beta of 1.03, suggesting that its share price is 3% more volatile than the broader market.

Repligen has higher revenue and earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adaptive Biotechnologies	$308.08M	13.05	-$59.50M	-$0.41	N/A
Repligen	$738.26M	13.48	$48.89M	$0.73	241.47

Summary

Repligen beats Adaptive Biotechnologies on 12 of the 17 factors compared between the two stocks.

Get Adaptive Biotechnologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ADPT vs. The Competition

Export

Metric	Adaptive Biotechnologies	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.02B	$10.11B	$7.20B	$12.90B
Dividend Yield	N/A	1.46%	2.54%	11.28%
P/E Ratio	-61.44	62.76	273.16	25.45
Price / Sales	13.05	111.64	604.87	76.92
Price / Cash	N/A	26.70	76.74	53.00
Price / Book	26.80	37.29	12.98	6.14
Net Income	-$59.50M	$56.67B	$3.48B	$348.86M
7 Day Performance	-3.08%	-1.52%	0.13%	-0.80%
1 Month Performance	4.18%	7.21%	7.08%	4.13%
1 Year Performance	91.12%	24.31%	24.67%	15.17%

Adaptive Biotechnologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ADPT Adaptive Biotechnologies	1.6889 of 5 stars	$25.19 -4.7%	$24.42 -3.1%	+91.1%	$4.02B	$308.08M	N/A	790	Positive News
CRL Charles River Laboratories International	2.6131 of 5 stars	$298.76 +1.2%	$255.65 -14.4%	+78.7%	$14.09B	$4.02B	N/A	19,700	Trending News Insider Trade Analyst Revision
RVTY Revvity	3.0585 of 5 stars	$123.08 -1.3%	$108.36 -12.0%	+42.9%	$13.92B	$2.91B	58.61	11,000	News Coverage Analyst Revision
ICLR Icon	3.2438 of 5 stars	$173.48 +0.7%	$170.40 -1.8%	-4.5%	$13.19B	$8.25B	40.72	40,100	Analyst Forecast
TECH Bio-Techne	3.4783 of 5 stars	$72.39 +0.1%	$68.92 -4.8%	+32.4%	$11.34B	$1.22B	62.95	3,100	News Coverage Positive News Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ADPT) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Adaptive Biotechnologies (ADPT) Competitors

ADPT vs. CRL, RVTY, ICLR, TECH, and RGEN

How does Adaptive Biotechnologies compare to Charles River Laboratories International?

Summary

How does Adaptive Biotechnologies compare to Revvity?

Summary

How does Adaptive Biotechnologies compare to Icon?

Summary

How does Adaptive Biotechnologies compare to Bio-Techne?

Summary

How does Adaptive Biotechnologies compare to Repligen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADPT vs. The Competition

Adaptive Biotechnologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Adaptive Biotechnologies (ADPT) Competitors

ADPT vs. CRL, RVTY, ICLR, TECH, and RGEN

How does Adaptive Biotechnologies compare to Charles River Laboratories International?

Does the media refer more to CRL or ADPT?

Which has stronger earnings & valuation, CRL or ADPT?

Do analysts recommend CRL or ADPT?

Is CRL or ADPT more profitable?

Do institutionals and insiders believe in CRL or ADPT?

Which has more risk and volatility, CRL or ADPT?

Summary

How does Adaptive Biotechnologies compare to Revvity?

Do analysts prefer ADPT or RVTY?

Which has more volatility & risk, ADPT or RVTY?

Which has preferable valuation and earnings, ADPT or RVTY?

Is ADPT or RVTY more profitable?

Does the media favor ADPT or RVTY?

Do institutionals and insiders have more ownership in ADPT or RVTY?

Summary

How does Adaptive Biotechnologies compare to Icon?

Does the media prefer ADPT or ICLR?

Which has more volatility & risk, ADPT or ICLR?

Do insiders & institutionals believe in ADPT or ICLR?

Do analysts recommend ADPT or ICLR?

Which has better earnings & valuation, ADPT or ICLR?

Is ADPT or ICLR more profitable?

Summary

How does Adaptive Biotechnologies compare to Bio-Techne?

Which has more risk and volatility, ADPT or TECH?

Do insiders & institutionals believe in ADPT or TECH?

Is ADPT or TECH more profitable?

Which has higher earnings & valuation, ADPT or TECH?

Does the media prefer ADPT or TECH?

Do analysts recommend ADPT or TECH?

Summary

How does Adaptive Biotechnologies compare to Repligen?

Do institutionals and insiders hold more shares of ADPT or RGEN?

Is ADPT or RGEN more profitable?

Do analysts recommend ADPT or RGEN?

Does the media refer more to ADPT or RGEN?

Which has more volatility and risk, ADPT or RGEN?

Which has preferable valuation and earnings, ADPT or RGEN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADPT vs. The Competition

Adaptive Biotechnologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools